SeromYx Systems, Inc. Appoints Andrew Ball, PhD, as Chief Executive Officer

Abigail Harris • February 5, 2025

Woburn, MA, February 5th, 2025 — SeromYx Systems, Inc. , a global leader in high-throughput antibody characterization and Systems Serology services, today announced the retirement of Chief Executive Officer, Mr. Piers Whitehead, a co-founder of the company, who will remain with the organization as a member of the Board of Directors and as a strategic advisor. Concurrently, as part of a planned transition, Andrew Ball, PhD has been appointed Chief Executive Officer and Director, effective February 4th, 2025.

Dr. Ball brings over 20 years of global leadership experience in the life sciences industry, with a successful track record in technical and commercial development of assay platforms and services. Most recently, he served as Vice President, Assay Development Platforms at Abcam, a Danaher company, where he led a global R&D organization developing and commercializing immunoassays, cell-based assays, antibody conjugates, recombinant proteins and contract assay services. He has also held roles as VP of Assay Development at Quanterix, developing ultrasensitive assays for neurodegenerative disease and immunooncology; as VP of R&D at Quad Technologies, a cell and gene therapy startup acquired by Bio-Techne, and has served in a variety of innovation and strategic leadership roles at MilliporeSigma.

Commenting on the appointment, Armin Spura, PhD, Executive Chairman of the Board of Directors said:

“On behalf of the Board, I want to thank Piers for his many contributions to SeromYx’s success since its founding. Under Piers’ leadership, SeromYx has grown to become successful and profitable, powered by the leading technology platform for Fc effector profiling. I am very pleased to announce the appointment of Dr. Andrew Ball as our new Chief Executive Officer. Andrew is a distinguished industry leader whose deep experience in assay development, insights into antibody development, and ability to bridge technical and commercial applications make him the ideal choice to lead SeromYx. We are confident that Andrew’s vision and strategic acumen will position SeromYx for continued success in the years ahead.”

Andrew Ball added:

“ I am excited to join SeromYx at this pivotal time as we continue to deliver for our clients and build on the strong foundations the company has established – with our comprehensive Fc effector function profiling platform. I believe SeromYx is uniquely positioned to deliver new insights into the correlation between function and clinical outcomes during therapeutic antibody discovery and development. “

The company extends its gratitude to Piers Whitehead for his leadership and contributions, which have positioned SeromYx for continued success.

About SeromYx Systems, Inc.:
SeromYx Systems, Inc. is a global leader in providing GCLP high-throughput antibody characterization and Systems Serology services, offering advanced solutions for the comprehensive analysis of immune responses and correlation of antibody function with clinical outcomes. With a dedication to innovation and excellence, SeromYx is at the forefront of revolutionizing the field of vaccine and therapeutic antibody development through its cutting-edge technologies and strategic collaborations.

Contact:
Abigail Harris
Business Development Manager
Abigail.harris@seromyx.com

< Older Post

Newer Post >

The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization

June 4, 2026

The Fc Review: When does antibody bivalency help, and when can it work against you? A recent mAbs study explores the impact of antibody bivalency on antigen occupancy and cell surface opsonization, revealing that the same property can be advantageous or disadvantageous depending on the intended mechanism of action (MoA). Background: Most therapeutic antibodies are bivalent, meaning they can bind two target antigens simultaneously. This avidity effect is often viewed as beneficial because it increases apparent binding strength and can improve target engagement. However, therapeutic success is not always driven by target occupancy alone. For mechanisms that rely on Fc-mediated effector function, the number of antibodies decorating the target cell surface may be just as important. The study highlights: Bivalent antibodies achieved higher antigen occupancy than comparable monovalent antibodies across a range of affinities and antigen densities. At the same time, bivalency reduced the total number of antibodies bound per cell because a single antibody could occupy two antigens simultaneously. The authors describe an "avidity barrier," where achieving equivalent levels of cell surface opsonization requires substantially higher concentrations of a bivalent antibody. The optimal balance between occupancy and opsonization depended on factors including antibody affinity, valency, and target antigen density.

A causal link between autoantibodies and neurological symptoms in long COVID

May 28, 2026

Abstract: Acute SARS-CoV-2 infection triggers the de novo production of diverse, functional autoantibodies (AABs) that remain elevated in Long COVID (LC), but their pathogenic role remains unclear. Using tissue-based immunofluorescence, ELISA, human protein array, and mass spectrometry assays, we identified a broad range of AAB targets among individuals with LC. Individuals with neurocognitive symptoms showed increased AABs against central and peripheral nervous system proteins. Purified IgG reacted with human locus coeruleus, thalamus, adrenal gland, thyroid, and cross-reacted with mouse sciatic nerve and meninges. CNS-reactive AABs correlated with several neurological symptoms. MED20-targeting IgG from patients with LC showed enhanced antibody-dependent phagocytosis. Passive transfer of IgG from individuals with LC into mice induced fatigue-like behavior, loss of balance/coordination, thermal hyperalgesia, small fiber nerve damage, and increased pain-related neuronal activity, recapitulating patients’ symptoms. These findings suggest that targeting AABs might offer therapeutic benefits for this LC subgroup.

World Vaccine Congress 2026

May 18, 2026

Type: Conference Dates: October 19th-21st, 2026 Location: Amsterdam, Netherlands

Vaccines Summit 2026

May 18, 2026

Type: Conference Dates: November 16th-18th, 2026 Location: Peabody, MA

Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges

May 18, 2026

The Fc Review: How much does Fc design influence the next generation of ADCs? A recent Cell review explores the rapid evolution of antibody-drug conjugates (ADCs), highlighting how advances in payloads, linker technologies, and antibody engineering are reshaping the field across both hematologic and solid tumors. Background: ADCs were originally developed as targeted delivery vehicles for highly potent payloads. But as the field matures, it is becoming increasingly clear that ADC activity is shaped by far more than antigen targeting alone. Factors such as linker stability, payload permeability, tumor microenvironment, bystander killing, and Fc-mediated interactions can all influence therapeutic performance. The study highlights: Fc-mediated mechanisms such as ADCC, ADCP, and complement activation can contribute to ADC activity beyond payload delivery. Some next-generation ADCs are intentionally engineered to enhance Fc effector function, while others incorporate Fc-silencing strategies to minimize off-tumor interactions. Payload selection, linker chemistry, and drug-to-antibody ratio all influence efficacy, safety, and bystander activity. Tumor antigen expression alone is often insufficient to predict ADC behavior, highlighting the importance of functional characterization and biological context.

Glycan pairing in therapeutic IgG orchestrates Fcγ receptor engagement and ADCC: an integrated structure-function approach for thorough evaluation of Fc N-glycans as critical quality attributes

April 21, 2026

The Fc Review: Are we oversimplifying Fc glycosylation? A recent study in mAbs explores how glycan pairing within IgG antibodies shapes Fcγ receptor engagement and ADCC, highlighting an often-overlooked layer of Fc biology. Background: Fc glycosylation is a well-known modulator of antibody function, influencing Fcγ receptor binding and downstream effector activity. However, each IgG contains two Fc glycans, one on each heavy chain, that can pair symmetrically or asymmetrically. Most analytical approaches report glycan composition as an average, without capturing how these glycans are distributed across individual molecules. This study asks a key question. Does glycan pairing itself influence Fc function? The study highlights: Fc glycan pairing, not just overall composition, influences Fcγ receptor binding across multiple receptors and allotypes A single afucosylated glycan was sufficient to drive enhanced FcγRIIIa binding and ADCC, with limited additional benefit from full afucosylation Galactosylation and high-mannose structures showed receptor- and context-dependent effects on Fc engagement Functional outcomes cannot be fully inferred from bulk glycan profiles, as different pairing configurations can produce distinct biological behavior

Impacts of Antibody Structure and Mixtures on Receptor Signaling for Antibody-Dependent Cellular Cytotoxicity

March 10, 2026

The Fc Review: How do antibody structure and binding dynamics shape ADCC signaling? A recent study in The AAPS Journal explores how multiple antibody design features, including Fab affinity, hinge flexibility, Fc engagement, and antigen density, influence antibody-dependent cellular cytotoxicity (ADCC) signaling. Background: ADCC is a key mechanism of action for many therapeutic antibodies, yet the strength of this response depends on more than Fcγ receptor binding alone. Productive immune activation requires antibodies to bridge target cells and effector cells within the immune synapse, forming receptor crosslinks that trigger downstream signaling. Using a combination of computational modeling and experimental data, this study examines how structural properties of antibodies influence these crosslinking events and ultimately shape ADCC signaling outcomes. The study highlights: ADCC signaling is influenced by multiple antibody properties, including Fab affinity, hinge flexibility, Fc receptor engagement, and antigen expression levels. Antibody structure affects how efficiently Fc receptors and target antigens are crosslinked within the immune synapse. In some cases, moderate Fab affinity supported stronger signaling by favoring productive crosslinking configurations. Antibody valency and hinge flexibility also influenced signaling outcomes by altering the geometry of immune synapse interactions.

Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling

February 12, 2026

The Fc Review: How well do our preclinical models capture human Fc biology? A new Science Immunology study takes a deep look at Fcγ receptor and FcRn expression across humans, non-human primates, and mice, highlighting how species-specific differences shape Fc-mediated immune function. Background: Fc-dependent activity is influenced not only by antibody design, but also by where and how Fcγ receptors are expressed across immune cell types and tissues. While animal models remain central to #antibody development, differences in Fcγ receptor biology across species can complicate interpretation of Fc-driven mechanisms. The study highlights: Species-specific differences in Fcγ receptor expression patterns across immune cell subsets and tissues. Context-dependent regulation of Fcγ receptors by inflammatory cues, with expression shifting across cell types and environments. These differences influence how Fc-mediated functions are engaged and interpreted across experimental systems. Cross-species variation in FcγR and FcRn biology helps explain why Fc-dependent effects observed preclinically may not always translate cleanly to human settings.

Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

January 21, 2026

The Fc Review: How are antibody developers actually using Fc engineering today? A recent analysis of the IMGT/mAb-DB database takes a systematic look at engineered Fc variants across therapeutic antibodies and fusion proteins, offering a real-world snapshot of how Fc design choices are being deployed in the clinic. Background: Fc engineering is often discussed in terms of individual mutations or isolated use cases. But at an industry level, it’s less clear how frequently Fc variants are used, which functions are prioritized, and whether antibodies rely on single or multiple Fc modifications. By mining curated entries in IMGT/mAb-DB, this study steps back to examine Fc engineering trends across approved and clinical-stage molecules. The review highlights: Fc engineering is widespread across therapeutic antibodies and fusion proteins cataloged in IMGT/mAb-DB Effector silencing strategies are commonly employed, particularly in programs prioritizing safety and controlled immune engagement Many molecules incorporate multiple Fc variants, rather than a single engineered change Fc modifications are used across a range of mechanisms and formats, underscoring Fc’s role as an intentional design lever

Generative design of antibody Fc-variants with synthetic and programmable functional profiles

December 4, 2025

The Fc Review: Continuing our series taking a closer look at recent Fc-focused papers, what they found, and why it matters for antibody discovery and development. Can we program the Fc region? A recent bioRxiv preprint explores this question at scale, using millions of Fc variants to train machine learning models that predict functional outcomes across FcγR interactions. Background: Through engagement with Fc-receptors, the antibody Fc domain can direct a broad range of immune activities, including phagocytosis, cytokine release, antigen presentation, and immune cell polarization – each of which could be precisely tuned to combat disease. Fc engineering has traditionally focused on modifying one property at a time (E.g., ADCC, ADCP, or half-life). This work instead treats the Fc region as a functional design space and explores how sequence variations across the Fc domain can be linked to real immune engagement.